Audentes Therapeutics (NASDAQ:BOLD) was upgraded by equities research analysts at BidaskClub from a “buy” rating to a “strong-buy” rating in a research note issued to investors on Wednesday, December 20th.
Several other analysts also recently weighed in on the company. Bank of America restated a “buy” rating and issued a $33.00 price target (up previously from $23.00) on shares of Audentes Therapeutics in a research note on Friday, September 22nd. Raymond James Financial initiated coverage on Audentes Therapeutics in a research note on Thursday, October 12th. They issued a “market perform” rating on the stock. William Blair initiated coverage on Audentes Therapeutics in a research note on Tuesday, October 17th. They set an “outperform” rating and a $35.00 target price on the stock. BMO Capital Markets initiated coverage on Audentes Therapeutics in a research note on Tuesday, December 5th. They set an “outperform” rating and a $35.00 target price on the stock. Finally, ValuEngine downgraded Audentes Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, December 1st. Two research analysts have rated the stock with a sell rating, one has given a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $35.00.
Audentes Therapeutics (BOLD) traded up $1.30 on Wednesday, reaching $37.47. The company’s stock had a trading volume of 344,682 shares, compared to its average volume of 406,481. The company has a market cap of $1,079.87, a price-to-earnings ratio of -10.74 and a beta of -0.21. Audentes Therapeutics has a fifty-two week low of $13.90 and a fifty-two week high of $41.80.
Audentes Therapeutics (NASDAQ:BOLD) last posted its earnings results on Tuesday, November 14th. The biotechnology company reported ($0.88) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.88). research analysts expect that Audentes Therapeutics will post -3.5 EPS for the current year.
In other Audentes Therapeutics news, Director Louis G. Lange sold 18,000 shares of the firm’s stock in a transaction dated Friday, December 22nd. The stock was sold at an average price of $30.88, for a total transaction of $555,840.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP Mary Newman sold 10,000 shares of the firm’s stock in a transaction dated Thursday, November 16th. The shares were sold at an average price of $26.84, for a total value of $268,400.00. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 36,000 shares of company stock worth $1,052,480. 47.30% of the stock is owned by insiders.
Large investors have recently bought and sold shares of the business. Redmile Group LLC grew its position in shares of Audentes Therapeutics by 77.8% during the second quarter. Redmile Group LLC now owns 1,459,616 shares of the biotechnology company’s stock valued at $27,922,000 after purchasing an additional 638,780 shares in the last quarter. Jennison Associates LLC grew its position in shares of Audentes Therapeutics by 182.4% during the second quarter. Jennison Associates LLC now owns 846,273 shares of the biotechnology company’s stock valued at $16,189,000 after purchasing an additional 546,617 shares in the last quarter. Vanguard Group Inc. grew its position in shares of Audentes Therapeutics by 130.3% during the second quarter. Vanguard Group Inc. now owns 678,412 shares of the biotechnology company’s stock valued at $12,978,000 after purchasing an additional 383,837 shares in the last quarter. Artal Group S.A. purchased a new position in shares of Audentes Therapeutics during the third quarter valued at about $5,602,000. Finally, State Street Corp grew its position in shares of Audentes Therapeutics by 231.6% during the second quarter. State Street Corp now owns 221,276 shares of the biotechnology company’s stock valued at $4,234,000 after purchasing an additional 154,544 shares in the last quarter. 78.95% of the stock is currently owned by institutional investors and hedge funds.
About Audentes Therapeutics
Audentes Therapeutics, Inc is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).
Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.